skip to main content

H.R. 5247: To authorize the use of eligible investigational drugs by eligible patients who have been diagnosed with a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or with another

This was a vote to pass H.R. 5247 in the House. This vote was taken under a House procedure called “suspension of the rules” which is typically used to pass non-controversial bills. Votes under suspension require a 2/3rds majority. A failed vote under suspension can be taken again.

It was not the final House vote on the bill. See the history of H.R. 5247 for further details.

H.R. 5247 authorizes the use of eligible investigational drugs by patients who have been diagnosed with certain illnesses, who have exhausted the approved treatment options and are not eligible to participate in a clinical trial.

The bill defines an eligible patient as those with “a stage of a disease or condition in which there is reasonable likelihood that death will occur within a matter of months, or a disease or condition that would result in significant irreversible morbidity that is likely to lead to severely premature death.”

The legislation allows for investigational drugs to be used if they have completed phase 1 of clinical trials, they have not been approved or licensed for any use under the Public Health Service Act, and an application has been filed that is active under the Public Health Service Act. The legislation removes liability on the manufacturer, sponsor, physician, hospital, or clinical investigator if the above conditions are met and there are not additional factors such as willful, criminal, or reckless misconduct or gross negligence, and removes liability if such an entity makes the determination not to provide the investigational drug. The bill requires doctors for such patients to report “serious adverse events” from the drug to the manufacturer. The legislation also strengthens patients protections with clearer informed consent and real-time adverse event reporting as well as a standard to notify the Food and Drug Administration (FDA) when a patient receives an unapproved drug through the new alternative pathway. The liability protections apply to both the existing expanded access program as well as the new alternative pathway, leveling the playing field by removing a perverse incentive to choose on program over the other.

Source: Republican Policy Committee

Totals

All Votes R D
Yea 60%
 
 
259
227
 
32
 
Nay 33%
 
 
140
2
 
138
 
Not Voting 7%
 
 
31
8
 
23
 

Date: Mar 13, 2018

Question: On Motion to Suspend the Rules and Pass in the House

Required: 2/3

Result: Failed

Source: house.gov

Ideology Vote Chart

Key: R Yea D Yea R Nay D Nay
Seat position based on our ideology score.

Cartogram Map

Each hexagon represents one congressional district.

What you can do

Vote Details

Notes: The Speaker’s Vote? “Aye” or “Yea”?
Download as CSV

Statistically Notable Votes

Statistically notable votes are the votes that are most surprising, or least predictable, given how other members of each voter’s party voted and other factors.

All Votes